SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

Never Miss a Story

Sign up for email alerts

 

More Industry Headlines

CMS report on medical homes finds no evidence of cost savings Concluding they don't work, however, 'a mistake'

UK researchers determine five types of prostate cancer Some are tigers, others are pussycats — knowing which is which could save lives

Music festival takes aim at regional heroin epidemic In New Jersey, drug addiction does not rock

Leidos, Cerner, Accenture, win highly sought Department of Defense EHR contract Military Health System contract worth at least $4.3 billion

Pantheon acquires IBSL, expands into biomedical service segment Will significantly increase footprint in Italian market

GE invests $1 billion to improve global training over next five years Over 300 million patients globally could benefit

Strength in numbers: The microbiome versus 'superbugs' New insight into how bacteria fight invasion could inform probiotic development

Certain cardiovascular factors may predict Alzheimer’s Alcohol, smoking, diabetes and obesity all increase risk

Genetic test predicts sensitivity of tumors to radiation therapy Customizing dose to a particular tumor instead of standard uniform dose

Is China the new frontier for medical equipment manufacturers? 'Made in China 2015' initiative aims to boost quality — and competitiveness

CMS panel says evidence lacking for Amyvid

By Brendon Nafziger and Loren Bonner

A Medicare advisory panel voted Wednesday there wasn't enough evidence to determine whether the PET amyloid drug Amyvid could help improve outcomes for patients with early signs of cognitive dysfunction. The decision by the panel, called the Medicare Evidence Development & Coverage Advisory Committee, could represent a setback in efforts to get national Medicare coverage for the drug, and potentially others that will be coming down the pipeline for amyloid PET imaging.

Story Continues Below Advertisement

Joint Commission changes are here! Are YOU ready?

As the leading Joint Commission accreditation service provider in the U.S., WEST PHYSICS knows these new requirements in depth. Click here to find out how WEST PHYSICS can help guide you successfully through the process.



The MEDCAC panel only judged evidence for the drug and has no authority to determine if Amyvid should be covered. However, the Center for Medicare and Medicaid Services relies on its advice to inform coverage decisions for new technology or procedures — in this case, with Amyvid for PET beta-amyloid imaging.

The Eli Lilly & Co. drug received FDA approval last spring. It's used in PET scans to help doctors measure beta-amyloid plaque load in the brain, which is associated with Alzheimer's disease.

According to the language of Amyvid's FDA approval, a positive scan is not diagnostic for Alzheimer's, but a negative scan could help physicians rule out the brain-wasting disease in favor of other types of dementia.

Backers of the agent say it can help change management of patients, but a majority of the expert panelists, made up of radiologists, neurologists and psychiatrists, thought the jury was still out on the drug.

"I just can't connect the dots between the current state of knowledge of the way the test performs and the outcome," Dr. Steve Gutman, a panelist and strategic advisor with Myraqa Inc., said at the meeting. "I don't think you can create a chain of evidence here that works."

In the vote, the panelists gave their confidence rating on the evidence an average of 2.2 on a five point scale, indicating lower levels of confidence. The panel also voted that the uncertainty applied to Medicare-aged populations, too.

"I think it's incredibly important to our patients and our physicians to have a biomarker like this available," said Dr. Jerrold Rosenbaum, the psychiatrist-in-chief at Massachusetts General Hospital. "The question is, this one and now, not whether we need it (in general)."

Skeptics on the panel said they wanted more studies that include enough patients with unexplained mild cognitive impairment, thought to benefit most from the scans, and they also wanted proof that the drug actually changed patient management.

The panel also expressed concern about potential overuse of the scans and the danger that false positives — positive scans of actually healthy people — could needlessly worry patients. "I'm not sure I have enough data to be able to weigh the benefits and harms of this particular technology in terms of that false positive aspect," Dr. Art Sedrakyan, an associate professor at Weill Cornell Medical School and vice-chair of the panel, said.

Continue reading CMS panel says evidence lacking for Amyvid ...
  Pages: 1 - 2 >>

Related:


Interested in Medical Industry News? Subscribe to DOTmed's weekly news email and always be informed. Click here, it takes just 30 seconds.

You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2015 DOTmed.com, Inc.
ALL RIGHTS RESERVED